UroGen Pharma Ltd. Segments Disclosure
NOTE 21 – Segment Reporting
The Company is engaged in the development and commercialization of innovative solutions for the treatment of urothelial and specialty cancers. The Company has a operating segment and reportable segment focused on these business activities, and its operations are managed on a consolidated basis. The primary revenue source for the segment comes from sales of the Company’s approved products, Jelmyto and Zusduri, primarily conducted in the United States.
The Company’s Chief Operating Decision Maker (“CODM”) is the Chief Executive Officer (“CEO”). The CODM assesses performance and allocates resources based on net income or loss, which is the primary measure of performance, as reported in the Consolidated Statements of Operations and Comprehensive Loss. Additionally, net income or loss is used to monitor performance relative to budgeted targets and to evaluate financial performance in relation to the Company’s strategic goals. For additional information, refer to the Consolidated Statements of Operations and Comprehensive Loss for detailed measures of segment revenues, expenses, and profit or loss.
Information about significant segment expenses regularly provided to the CODM is as follows (in thousands):
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Research and development expenses | ||||||||
| R&D project materials & services | $ | 46,150 | $ | 38,556 | ||||
| Employee compensation | 17,286 | 14,882 | ||||||
| Rent, office, utilities & technology | 3,047 | 2,972 | ||||||
| Other expenses | 624 | 735 | ||||||
| Total research and development expenses | $ | 67,107 | $ | 57,145 | ||||
| Selling, general and administrative expenses | ||||||||
| Employee compensation | $ | 77,868 | $ | 59,709 | ||||
| Commercial & medical affairs services | 34,747 | 27,205 | ||||||
| Professional services | 14,221 | 14,031 | ||||||
| Travel, meetings & conferences | 16,383 | 12,962 | ||||||
| Rent, office, utilities & technology | 4,979 | 3,283 | ||||||
| Other expenses (1) | 6,899 | 3,964 | ||||||
| Total selling, general and administrative expenses | $ | 155,097 | $ | 121,154 | ||||
(1) Other expenses primarily consist of insurance, sponsorship, grants, other fees and taxes.
Want the next UroGen Pharma Ltd. segments disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment UroGen Pharma Ltd.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 2, 2026 | Showing above |
| 2024 | Mar 10, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.